The Food and Drug Administration on Monday approved a treatment for cystic fibrosis that combines Vertex Pharmaceuticals Inc’s Kalydeco with another medicine, Vertex said, marking the company’s third product for the life-shortening lung disorder, according to Reuters.

The list price of SYMDEKO is $292,000 per year, but that is not the price patients pay. Vertex shares rose about 2 percent to $154.92 in extended trading after the approval was announced about two weeks ahead of an expected FDA action date.